STI-1558, an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of COVID-19. Studies to date indicate that STI-1558 does not ...

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor ...

Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients ...

Two months after pandemic lockdowns began, San Diego biotech Sorrento Therapeutics put out a hopeful press release on a COVID-19 breakthrough that some took to tout a cure. 9th Circuit opinion ...

The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China. During the trial, Ovydso has maintained ...

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New ...

Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60 ...

Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA ...

Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both ...

Sorrento Therapeutics announced that it received a study may proceed letter from the US FDA for its phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients. As Sorrento ...

(Reuters) - Sorrento Therapeutics Inc on Friday partnered with New York City's Mount Sinai Health System to develop an antibody cocktail to potentially treat or prevent COVID-19, with the aim of ...

In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO™ (Olgotrelvir) or placebo. The ...